Shanghvi Gives Sun An M&A Dose Of Growth
Pharma billionaire sees 63% rise in net worth as acquisitions pay off.
pharma sector
September 2024
August 2024
July 2024
February 2024
April 2023
February 2023
January 2023
Dilip Shanghvi Richest Pharma Entrepreneur
Sun Pharma chairman leads the pack with a net worth of ₹2.32 lakh cr; Cyrus Poonawalla follows with ₹1.71 lakh crore.
India waives off clinical trials for 5 drugs approved in US, UK, EU, Japan, Australia, Canada
DCGI lists categories of drugs eligible for this concession, including orphan drugs for rare diseases and new drugs used in pandemic situations
Budget 2024: Pharma, health, med-tech sectors seek tax tweaks
Indian Pharmaceutical Alliance, an association of 23 leading pharma companies, seeks direct and indirect tax benefits from Budget to encourage research and investment in pharma sector
Budget 2024: Pharma sector seeks quick approval process and tax benefits
Digitising regulatory submissions is expected to accelerate drug approvals, while new tax benefit policies are anticipated to boost R&D
Budget 2024: Will budget allocation for pharma sector increase this year?
The industry expects an enhanced healthcare spend of 2.5% of GDP to boost infrastructure and R&D activities.
Mankind Pharma to launch IPO this month; looks to raise around ₹4,700 cr
The IPO of the country’s fourth largest pharma company by domestic sales comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.
Budget 2023: 'Amrit Kaal' budget fails to give booster dose for pharma & healthcare
Budget allotted ₹89,160 crore for healthcare sector for FY2024, less than 3% increase from previous year. In FY23, spending on healthcare was only 2.1% of GDP.
USFDA inspections to be less disruptive for Indian pharma sector: Report
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
Budget 2023 may offer Research Linked Incentive scheme for Indian pharma
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
